Allogene Therapeutics, Inc. (ALLO) Earnings Call Transcripts
Allogene Therapeutics, Inc.'s Latest Earnings Call - April 13, 2026
In the first quarter of fiscal year 2026, Allogene Therapeutics, Inc. reported significant progress in its pivotal Phase II ALPHA 3 trial for Semacell, an allogeneic CAR-T therapy for large B-cell lymphoma. The interim futility analysis revealed a 58.3% MRD clearance rate in the treatment group compared to 16.7% in the observation arm, exceeding the clinical meaningful benchmark of 25% to 30%. Management emphasized the potential market opportunity of $2.5 billion to $3.5 billion for Semacell, indicating a strategic shift towards earlier intervention in treatment paradigms, which could redefine patient care and expand access to CAR-T therapies.
Reported metrics
| Metric | Value |
|---|---|
| MRD Clearance Rate | 58.3% (beat) |
| Market Opportunity (Total Addressable Market) | $5 billion (positive) |
| Semacell Market Potential | $2.5 billion to $3.5 billion (positive) |
| Projected MRD Testing Rate | 75%-80% (positive) |
| Enrollment Completion Timeline | End of 2027 (neutral) |
| Interim EFS Analysis | Mid-2027 (neutral) |
Guidance from management
Management maintained a positive outlook on the potential for Semacell, emphasizing the importance of the upcoming interim EFS analysis in mid-2027 and the possibility of accelerating regulatory discussions based on interim results.
What management said
Thank you, Dr. Sharma. As someone who has long been at the forefront of community-based cancer research, please provide your perspective on some of the gaps and access to CAR-T specifically for patients who receive care outside of academic settings.
Great. So how might these early safety and efficacy data, if they bear out in the overall study, change how you think about offering CAR-T to your patients -- and how do you think it might change to other patients and other community-based practices?
What analysts pressed on
Analysts expressed concerns regarding the broader adoption of CAR-T therapies in community settings and the logistical challenges associated with treatment delivery. There were questions about how the interim results would influence patient enrollment and the regulatory pathway moving forward.
Main topics on the call
- Interim Futility Analysis Results — The interim futility analysis from the ALPHA 3 trial showed a 58.3% MRD clearance rate for Semacell, significantly higher than the 16.7% in the observation group, representing a 41.6% absolute improvement. Management sta...
- Safety Profile of Semacell — Management reported that Semacell was generally well tolerated with no cases of CRS or ICANS, which is notable given the historical toxicity associated with CAR-T therapies. Dr. Zachary Roberts noted, "The absence of any...
- Market Opportunity — The total addressable market for first-line consolidation in large B-cell lymphoma is estimated at approximately $5 billion, with Semacell's potential share being $2.5 billion to $3.5 billion. Management highlighted that...
- Physician Adoption and Market Research Insights — Market research indicated that physicians are increasingly recognizing the need for earlier intervention in CAR-T therapy, with projected MRD testing rates potentially increasing to 75%-80%. Management stated, "Physician...
Read the full Allogene Therapeutics, Inc. transcript (April 13, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. (ALLO) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 55 calls on record spanning January 13, 2020 to May 13, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 55 Allogene Therapeutics, Inc. earnings call transcripts on record, spanning January 13, 2020 to May 13, 2026. Based on this history, Allogene Therapeutics, Inc. reports quarterly. The most recent call on file is dated May 13, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- ALLO
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 55
- First call
- January 13, 2020
- Most recent
- May 13, 2026
- Reporting cadence
- quarterly